In 2D-hiPSC-SI treated with Irsogladine before ASA addition, LY permeability in the ASA + Irso group was significantly lower than in the ASA 400 µg/mL group. In the PDE4B1 assay, Irsogladine inhibited PDE activity by 20 and 31 % at 50 and 100 μM, respectively. In Caco-2 cells treated with Irsogladine at 200 μM for 24 h, AP-1 and NF-κB transcriptional activities decreased by 47% and 38% of the untreated control value, respectively. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Irsogladine with ASA reduces LY permeability
Cell-based study · 2D-hiPSC-SI; n = 3 [1]
In 2D-hiPSC-SI, Irsogladine at 16 µg/mL was applied to the basal side for 24 h before ASA addition. LY permeability in the ASA + Irso group was significantly lower than in the ASA 400 µg/mL group.
Literature-Reported Treatment Conditions
- Treatment concentration
- 16 µg/mL
- Exposure duration
- incubating for 24 h before ASA addition; Samples were collected 24 h after ASA addition.
- Method
- to the basal side of 2D-hiPSC-SI
- Vehicle
- basal medium
- Co-treatment
- Other interventions in this design: ASA 400 µg/mL. Compound effect isolated by the comparison: LY permeability of the ASA + Irso group was significantly lower than that of the ASA 400 µg/mL group.
Methods and source locations
Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine
Evidence for Irsogladine as the maleate form reported in the paper, not the free base/neutral form supplied as A10480; no salt equivalence, dose conversion or lot validation.
2. Materials and Methods > 2.3. Evaluation of the Effect of Irsogladine on ASA-Induced Small Intestinal Injury (S15, S16); 3. Results > 3.5. Irsogladine Plays a Protective Role against ASA-Induced Injury in 2D-hiPSC-SI (S90, S91); Figure 4 legend (S126); Figure 5 legend (S130, S132, S137)
LY permeability: LY permeability; comparator: ASA 400 µg/mL group — Figure 5 legend (S137)
Irsogladine inhibits PDE activity
Cell-based study · 10U PDE 4B1 (BPS Biosciences) [2]
In the PDE4B1 assay, Irsogladine was tested at 50 and 100 μM with DMSO as the vehicle control. PDE activity was inhibited by 20 and 31 %, respectively.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 and 100 μM
- Exposure duration
- for 20 min. After incubation, the cAMP substrate (final concentration 1.25 µM) was added and incubated for 1 h.
- Method
- incubated with reference and tested compound
- Vehicle
- dimethyl sulfoxide (DMSO)
Methods and source locations
Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Protocols for in vitro experiments > The phosphodiesterase 4B1 (PDE 4B1) activity assay (S110, S112, S113, S115, S116, S117); Results > The phosphodiesterase 4B1 (PDE 4B1) assay (S252); Table 2 legend (S289)
Inhibition of PDE4B1: Inhibition of PDE4B1; comparator: DMSO as vehicle control — Materials and methods > Protocols for in vitro experiments > The phosphodiesterase 4B1 (PDE 4B1) activity assay (S110); Results > The phosphodiesterase 4B1 (PDE 4B1) assay (S252)
Irsogladine decreases transcriptional activities in Caco-2 cells
Cell-based study · Caco-2 cells [3]
Caco-2 cells were treated with Irsogladine at 200 μM for 24 h. AP-1 and NF-κB transcriptional activities decreased by 47% and 38% of the untreated control value, respectively.
Literature-Reported Treatment Conditions
- Treatment concentration
- 200 μM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Irsogladine; Compound label in the paper: Irsogladine Irsogladine
Evidence for Irsogladine as the maleate form reported in the paper, not the free base/neutral form supplied as A10480; no salt equivalence, dose conversion or lot validation.
RESULTS > The effects of six gastric mucosal protectants on AP-1, NF-κB, NRF2, p53 and STAT3 transcriptional activity in Caco-2 cells (S1, S2); Figure 2 legend (S117, S119)
AP-1 transcriptional activity: AP-1 transcriptional activity; comparator: without the test reagent — RESULTS > The effects of six gastric mucosal protectants on AP-1, NF-κB, NRF2, p53 and STAT3 transcriptional activity in Caco-2 cells (S2); Figure 2 legend (S119)